Safety and efficacy of lobaplatin combined with 5-fluorouracil as first-line induction chemotherapy followed by lobaplatin-radiotherapy in locally advanced nasopharyngeal carcinoma: preliminary results of a prospective phase II trial

Table 5 Acute adverse events in 59 patients

Adverse events	No. (%) of patients by toxicity grade during ICT				No. (%) of patients by toxicity grade during CRT
Adverse events	1	2	3	4	1	2	3	4
Hematological
Anemia	28(47.5)	4(6.8)	0(0)	0(0)	22(37.3)	13(22.0)	10(16.9)	0(0)
Neutropenia	17(28.8)	17(28.8)	4(6.8)	1(1.7)	13(22.0)	22(37.3)	13(22.0)	2(3.4)
Leucopenia	20(33.9)	14(23.7)	4(6.8)	0(0)	14(23.7)	20(33.9)	20(33.9)	0(0)
Thrombocytopenia	9(15.3)	10(16.9)	3(5.1)	0(0)	4(6.8)	20(33.9)	16(27.1)	8(13.6)
Days of grade 3 or greater thrombocytopenia					≤7	8-14	≥15
Days of grade 3 or greater thrombocytopenia					17(28.8)	6(10.2)	1(1.7)
Non-hematological
Allergy	0(0)	0(0)	0(0)	0(0)	0(0)	0(0)	0(0)	0(0)
Weight loss	5(8.5)	0(0)	0(0)	0(0)	33(55.9)	5(8.5)	0(0)	0(0)
Stomatitis (mucositis)	2(3.4)	1(1.7)	1(1.7)	0(0)	49(83.1)	8(13.6)	2(3.4)	0(0)
Nausea	21(35.6)	2(3.4)	0(0)	0(0)	14(23.7)	6(10.2)	0(0)	0(0)
Vomiting	9(15.3)	2(3.4)	0(0)	0(0)	7(11.9)	6(10.2)	0(0)	0(0)
Diarrhea	1(1.7)	0(0)	0(0)	0(0)	1(1.7)	0(0)	0(0)	0(0)
Hepatotoxicity	21(35.6)	3(5.1)	2(3.4)	0(0)	23(39.0)	3(5.1)	2(3.4)	0(0)
Nephrotoxicity	10(16.9)	0(0)	0(0)	0(0)	11(18.6)	0(0)	0(0)	0(0)
Cardiotoxicity	0(0)	0(0)	0(0)	0(0)	0(0)	0(0)	0(0)	0(0)
Ototoxicity	0(0)	0(0)	0(0)	0(0)	10(16.9)	0(0)	0(0)	0(0)
Neurotoxicity	0(0)	0(0)	0(0)	0(0)	0(0)	0(0)	0(0)	0(0)
Joint and muscular ache	0(0)	0(0)	0(0)	0(0)	0(0)	0(0)	0(0)	0(0)
Alopecia	1(1.7)	0(0)	0(0)	0(0)	59(100)	0(0)	0(0)	0(0)

ISSN: 1471-2407